Chapter 2: Drug Development & Ethical Considerations in Nursing

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today, we are pulling back the curtain on something that

most of us take for granted every single time we swallow a pill.

Oh, absolutely.

You look at that little white tablet and you just assume it's safe.

You assume it works and you assume that someone somewhere make sure it wouldn't kill you.

And that assumption is, I mean, it's the very bedrock of modern medicine.

But what's so fascinating is how much like blood, sweat, money and legislation had to happen to make that assumption even remotely possible.

I was looking at the numbers in our source material for this Deep Dive specifically about drug development and they are frankly staggering.

I think people had this idea that a scientist has a eureka moment in a lab, mixes two beakers and then boom, you have a cure on the shelf next week.

Which could not be further from the truth, not even close.

Right.

To bring a single new drug to market, we are looking at a timeline of 12 years, sometimes more.

At least 12 years.

And the cost, it's just astronomical.

We're talking about an investment somewhere between 314 million and $2 .8 billion.

A billion.

With a B.

For one.

For one successful drug.

And that price tag, you know, it isn't just for the chemicals or the fancy lab equipment, it's the cost of failure.

The reality is that about 90 % of drugs that start that clinical journey fail to reach the market.

90%.

90.

They die on the vine.

That is a brutal attrition rate.

Investors must just hate those Well, they certainly don't love them.

But from a scientific and a safety perspective, that 90 % failure rate is actually a feature, not a bug.

It means the system is working, it's filtering out the compounds that lack clinical efficacy, meaning, you know, they just don't work.

Or even more alarmingly, the ones that have unmanageable toxicity.

So if a drug makes it to your pharmacy shelf, it is essentially the lone survivor of a 12 year gauntlet.

Exactly.

It's the survivor, the one out of 10 that made it through.

So our mission today is to walk through that gauntlet.

We are doing a deep dive into drug development and ethical considerations based on chapter two of the text.

A really foundational chapter.

And we aren't just looking at the chemistry here.

We're looking at this through the lens of the nurse, the person at the very, very end of that long supply chain, who actually hands the medication to the patient, which is such a critical distinction.

If you are a nursing student or really anyone involved in healthcare,

you can't view pharmacology as just a list of chemicals to memorize.

You have to understand the massive system of rules, the ethical frameworks, and all the historical hard lessons that govern practice.

It explains why you have to count every single pill, why you have to witness a signature on a form, and why you have to report a side effect, no matter how minor it seems.

We have a lot of ground to cover.

We're going to look at the engine of FDA approval and how it's evolving.

We're going to get into the really heavy ethical stuff, the Belmont Report principles that keep us from repeating the horrors of medical history.

And we need to.

We'll build a hypothetical drug and walk it through all the phases of research, from the lab bench to the post -market world.

Yeah, from test tube to patient.

And we're going to do a serious deep dive into the history of legislation from the wild west of 1906 to the modern day before wrapping up with the practicalities of drug names and the hidden dangers of over -the -counter meds.

It's a comprehensive journey, for sure.

It is.

So let's start with the current landscape.

We know it takes 12 years and billions of dollars, but is the machinery actually churning anything out?

It is, yeah.

If you look at the data from the FDA,

the US Food and Drug Administration approval rates for new drugs have been relatively steady since the early 2000s.

It's not an exponential curve.

It's more of a steady stream.

We saw a pretty significant peak back in 2018 with 59 novel drugs approved.

More recently in 2022, there were 37 novel drugs.

And when we use the term novel here, we aren't just talking about a new flavor of aspirin.

Oh no, not at all.

We are talking about new molecular entities, truly new compounds that been approved for marketing ever before.

But the raw number tells less of a story than the type of drugs being approved.

There has been a really strategic shift in the last two decades.

This connects to the critical path initiative that's mentioned in the text.

Precisely.

Back in 2004, the FDA basically had this realization that while science was advancing at lightning speed, genomics, proteomics, all of that, the actual process of product development was lagging behind.

The tools were old.

The tools to evaluate drugs were outdated.

So the critical path initiative was a strategy to modernize the entire scientific process of developing and evaluating medical products.

And one of the big byproducts of that modernization was a shift in focus toward neglected disorders.

Right.

For a long, long time, the market drove drug development.

If millions of people had a condition, high cholesterol, for example, companies made drugs for it.

Because that's where the money was.

Exactly.

But if only a few thousand people had a condition, well, those patients were often just out of luck.

The initiative really pushed to improve prevention, diagnosis, and treatment for these rare and neglected disorders.

So has that push actually worked?

Has it made a difference?

The data suggests it absolutely has.

If you look at those 2022 stats again, it's quite remarkable.

54 % of the novel drugs approved that year were for rare diseases.

Wow.

More than half.

More than half.

That is a massive operational shift.

We went from this model of blockbuster drugs for everyone to highly targeted therapies for the few.

We did.

And the text highlights some specific examples that might sound obscure to the general public, but are, I mean, miraculous for the patients involved.

Like what?

We're talking about treatments for things like generalized pustular psoriasis, or obstructive hypertrophic cardiomyopathy, or even heptarenal syndrome.

These are conditions that previously might've just had symptom management at best.

At best.

And now they have targeted therapies.

But getting those therapies approved requires navigating that rigorous, expensive, time -consuming development process we mentioned.

Okay.

So before we even get into the mechanics of those phases, phase one, phase two, all that, we have to talk about the rules of the road.

The ethical framework.

Because unlike testing a bridge design or a computer chip, we are testing these things on biological,

living, breathing human beings.

And that changes everything.

It's not just about data points.

Research involving human subjects involves a profound ethical weight.

The framework we use to navigate this today comes largely from the Belmont Report.

The Belmont Report is one of those foundational documents in bioethics, isn't it?

It is.

It established three core ethical principles that are echoed by the World Medical Association's Declaration of Helsinki.

And if you are a nurse, these aren't just abstract ideas you learn for a test.

No.

They are the checklist for patient advocacy.

The three principles are respect for persons, beneficence, and justice.

Let's break these down because I think the nuance here is really important.

Let's start with the respect for persons.

On the surface, that sounds like, you know, be polite, but it's much, much deeper.

Much deeper.

At its core, respect for persons is about autonomy.

It posits that patients should be treated as independent persons who are capable of making decisions in their own best interests.

So it's the recognition that the patient is the ultimate owner of their body and their choice.

In healthcare, we call this the right to self -determination.

A patient has the right to refuse a treatment, even if we as healthcare providers think it's a terrible idea.

Even if we think it's life -saving.

Even then.

If they are an autonomous adult, they get to say no.

End of story.

But the principle has a second half, doesn't it?

Because not everyone is an autonomous adult.

Right.

And this is key.

The principle explicitly states that patients with diminished decision -making capacity are entitled to protection.

This could be children, patients with advanced dementia, or maybe someone in a coma.

And this is where the nurse's role becomes incredibly active, right at the bedside.

It is.

The nurse is often the one there assessing that capacity.

Is the patient confused?

Are they under the influence of sedatives?

Do they actually understand what is being asked of them?

It's a judgment call.

A huge one.

If a patient can't make an autonomous choice, the principle of respect for persons shifts from let them decide to we must protect them from harm.

Now I want to touch on a specific exception mentioned in the text regarding the right to refuse.

We said patients can almost always say no.

But there is a little carve out for tuberculosis.

Yes, this is a fascinating intersection of individual rights versus public safety.

Because tuberculosis poses such a direct airborne threat to the community,

taking medication can actually be legally mandated in that specific instance.

So public health trumps individual autonomy there?

In that one rare case, yes.

But that is the exception that proves the rule.

Generally, in research, a patient can refuse to participate or, and this is crucial, they can withdraw from a study at any time, for any reason, without penalty.

And without penalty is the key phrase.

You can't say, well, if you quit the study, we're not going to treat your other conditions anymore.

No, that would be coercion.

Pure and simple.

Okay, so that's respect for persons.

Let's move to the second principle,

beneficence.

Beneficence.

This is the duty to protect research subjects from harm.

It sounds simple, the old do no harm adage.

But in research, we don't always know what the harm will be.

Right, that's why we're doing the research in the first place.

Exactly.

So this is where the risk -benefit ratio comes in.

It's a calculation.

It's a calculation, a balancing act.

The researcher, and just as importantly, the institutional review boards or IRBs that oversee them, must analyze all the potential risks.

Physical, psychological.

Physical, psychological, social risks.

All of it.

And they have to weigh those against the potential benefits.

So if the risk is high,

the potential benefit needs to be astronomical.

Correct.

You wouldn't test a drug with severe life -threatening side effects just to treat a mild headache.

But you might accept those same risks for a late -stage cancer treatment where there are no other options.

Make sense.

But the text adds a really sobering reminder here.

We cannot predict the future.

Despite all our careful calculations, risks are inherent.

Which brings us to the third principle, justice.

This is the one that I think hits hardest when you look back at the history of medical research.

It does.

Justice, in this context, is all about fairness and selection.

It demands that research subjects reflect all social classes, racial, and ethnic groups.

We can't just outsource the risk to the most vulnerable populations.

Precisely.

Historically, there was a terrible tendency to conduct risky research on prisoners or the poor or institutionalized populations.

People who couldn't easily say no.

Exactly.

While the benefits of that research, the shiny new drugs, went to the wealthy and the privileged,

justice says that the distribution of benefits and burdens must be equitable.

If a drug is meant for everyone, the testing pool should look like everyone.

So we have these three high -minded principles.

Respect, beneficence, justice.

But how do we actually operationalize them?

How do we prove we are following them?

That brings us to the paperwork.

Informed consent.

Informed consent is the mechanism.

It's the tool that ensures the principle of respect for persons is actually happening.

And it has a dark history.

It does.

Its roots go back to the 1947 Nuremberg Code, which was established after the horrific trials regarding human experimentation during World War II.

The two big takeaways from Nuremberg were the right to be informed and the absolute requirement for voluntary participation.

Voluntary meaning no coercion.

And coercion can be really subtle.

It's not always a gun to the head.

It can be offering huge sums of money to desperate people or implying that their regular medical care will suffer if they don't say yes.

Now, for the nursing students listening, there is a very clear stay -in -your -lane warning here when it comes to informed consent.

A very big one.

This is a critical distinction in scope of practice.

It is the role of the health care provider.

So the doctor, the nurse practitioner, the principal investigator to explain the study.

They're the expert on the research.

They're the ones who must explain the purpose, the procedures, the risks, the benefits, and answer the patient's specific questions about the research data.

So the nurse isn't the one doing the sales pitch for the study?

No, not at all.

The nurse is the patient advocate.

The nurse's role is to ensure the patient actually understands what was just said.

We are the backstop.

So you're checking for comprehension.

We assess for alertness.

We assess for confusion.

And we protect the patient if we suspect for a second that they are being coerced or don't get it.

But the nurse isn't the one explaining the complex mechanism of the experimental molecule.

Exactly.

If the patient holds up the pen to sign and says, wait a minute, I still don't get what this drug does to my liver.

The nurse doesn't add live an explanation.

The nurse pauses the signing, puts the pen down, and gets the provider back in that room.

Let's talk about the consent form itself.

These things can be pages and pages long.

But there are rules about how they have to be written.

There are.

The guidelines state that consent form should be written at or below an eighth grade reading level.

Eighth grade?

That seems surprisingly low for, you know, complex medical trials.

I mean, we're talking about pharmacokinetics and stuff.

We are.

But we're also talking to people who are often sick, scared, and under a tremendous amount of stress.

Health literacy varies wildly across the population.

That's a great point.

You cannot use jargon.

The guideline is to keep words to fewer than three syllables whenever possible.

If the patient can't understand the form, they aren't truly informed, are they?

No.

Valid consent requires comprehension.

The text provides a checklist of what has to be on that form.

It's quite the laundry list.

It is.

It has to explicitly state that the study involves research.

It has to detail the purpose, the duration, and all the procedures.

It also has to clearly separate standard care from the experimental procedures.

Okay.

We are going to draw your blood anyway for your regular care.

But this extra vial of blood is for the study.

Precisely.

It must list all the reasonably foreseeable risks and any potential benefits.

It has to list the alternatives.

What happens if I say no?

Can I still get treated?

All the options.

It covers confidentiality, any compensation, and contact info for questions.

And in what is effectively bold letters, it must state that participation is voluntary and they can withdraw at any time.

And before a researcher even hands that form to someone, they have to decide who to hand it to.

This is the concept of inclusion and exclusion criteria.

Right.

You can't just test a new heart drug on random people off the street.

To get scientifically valid data, you need a controlled,

specific population.

So inclusion criteria are the traits the subjects must have.

Correct.

For example, must be between ages 18 and 65, must weigh between 50 and 100 kilograms, and must be on a stable dose of their current cardiac meds.

And exclusion criteria are the opposite.

These are the deal -breakers.

Traits that would either make the study dangerous for that person, or just completely mess up the data.

Like what?

Common examples are pregnancy or nursing,

or having abnormal lab values at the start, or specific comorbidities like.

You wouldn't want someone with severe kidney failure in a study for a drug that's cleared by the kidneys.

Right.

That would be a disaster.

It would skew everything.

Okay.

So we have our ethical framework.

We have our consent forms, our patient selection process.

Now let's build a drug.

Let's do it.

Let's imagine we are developing Cardiocalm, a new blood pressure medication.

Let's walk Cardiocalm through the phases of pharmaceutical research.

Okay.

Good idea.

Before Cardiocalm ever touches a human being, it has to survive the preclinical trials.

Dissolve the lab work.

This is in vitro, which means in test tubes and cell cultures, and in vivo, which means animal testing.

What are we asking the animals?

What's the goal there?

We are asking some very basic but critical questions.

Is this thing toxic?

What are its pharmacologic effects?

And specifically, we are looking for genotoxicity.

Does this drug damage genetic information?

Does it cause mutations?

We are also mapping out the basics of ADME.

Absorption, distribution, metabolism, excretion.

If it kills the lab rats or mutates their DNA, Cardiocalm goes right in the trash.

It never sees a human.

But let's say Cardiocalm is safe in animals.

Now we move to human clinical experimentation, phase I.

Phase I is small.

We are talking about a very small group of volunteers,

and they are usually healthy.

Healthy.

So they don't even have the high blood pressure we're trying to treat.

Usually not, no.

The goal of phase I isn't to see if the drug works.

The goal is to see if it's safe in humans.

We're carefully determining the safe dosage range and identifying any immediate side effects.

We are answering the simple question, does this hurt a human being?

Okay,

so Cardiocalm doesn't hurt the healthy volunteers.

We figured out the safe dose.

Now what, phase II?

Now phase II.

Now we find a larger group of people, maybe a few hundred, who actually have the disease.

In this case, people with high blood pressure.

So now we are finally asking, does it work?

Exactly.

Phase II is all about effectiveness.

Does Cardiocalm actually lower blood pressure?

And of course, we're still watching very, very closely for safety.

If it works, we go to the big show, phase III.

Phase III involves large groups.

We are talking hundreds or even thousands of patients across multiple locations.

We are confirming its effectiveness.

We are monitoring side effects in a much more diverse population.

And typically, we are comparing it to commonly used treatments that are already out there.

So is Cardiocalm better than the generic stuff that's already on the shelf for a dollar a pill?

Or is it at least as good, but with fewer side effects?

This is where the study design becomes absolutely crucial.

We have to control for all the variables.

Let's pause on study design for a second.

The text mentions independent and dependent variables.

In our Cardiocalm example, what are those?

OK, so the independent variable is the thing we're testing, the thing we're changing.

So that's the drug Cardiocalm.

And the dependent variable.

That's the outcome we're measuring, the blood pressure reading.

The effect depends on the cause.

And then you have the intervening variables, which is just the messiness of life.

It is.

Age, sex, diet, smoking status, exercise, you name it.

If everyone in the Cardiocalm group suddenly quits smoking and starts jogging every day, their blood pressure will probably go down.

We won't know if it was the drug or the jogging.

Exactly.

That's why you have to have a control group.

The group that doesn't get the new drug.

Right.

They might get a placebo, a sugar pill, or they might get the current standard treatment.

By comparing the experimental group to the control group, we can isolate the effect of our drug Cardiocalm.

So let's say Cardiocalm passes phase three with flying colors.

The FDA gives it the stamp of approval.

It's in the pharmacy.

Are we done?

Nope.

Not at all.

We now enter phase three.

This is post -marketing surveillance.

Why is this necessary?

It's already approved.

Because even a large phase three trial only tests a few thousand people under very controlled conditions.

When you release a drug to millions of people in the real world, you start to see rare events.

Things you'd never catch in a smaller group.

Right.

Maybe it causes a specific strange reaction in one out of every 50 ,000 people.

You would never ever catch that in phase three.

Phase four is all about finding those rare long -term effects and identifying those outliers in the general population.

Now, in all these phases, there's a historical elephant in the room regarding who we test these drugs on.

Yes.

For a very long time, clinical drug research was biased heavily toward white males.

Why was that?

It was often viewed as cleaner data, no hormonal cycles in women to worry about, less genetic variation.

It was just simpler.

But the result was that we had all these drugs on the market where we simply didn't know if they worked the same way in women or in people from different ethnic backgrounds.

Or if the dosage needed to be completely different.

Exactly.

This led to the NIH Revitalization Act of 1993,

which mandated the inclusion of women and minorities in clinical research.

It basically forced science to deal with the complexity of the actual human population.

We've talked about the slow nature of this 12 -year process, but surely there has been pressure to speed things up.

Oh, huge pressure.

Especially during the HIV AIDS crisis in the 80s and early 90s.

This pressure led directly to the Prescription Drug User Fee Act in 1992.

How did that work?

It sounds a bit strange, but it basically allowed the FDA to collect fees from drug manufacturers to fund their own review process.

Like paying the referee.

It kind of sounds like that, but practically what it did was give the FDA the resources to hire more reviewers and modernize their systems.

It cut the average approval time from a staggering 30 months down to about 12 months.

Wow.

A huge change.

Now, overseeing the nurses' behavior in all this research is our own code.

The ANA Code of Ethics.

The American Nurses Association Code of Ethics.

It was founded on Florence Nightingale's principles.

I mean, she was the original data -driven nurse, the first true nursing researcher.

The code was updated in 2015 to handle modern issues like social media and electronic health records.

But the core principle is the same.

The nurse's primary commitment is always to the patient.

So it effectively says that even if you're working on a research study, you are a nurse first and a researcher second.

Correct.

Your patient's safety and well -being always come before the integrity of the data.

Safety and clinical judgment are paramount.

In the assessment phase, you're identifying eligible patients.

In planning, you're ensuring the consent process is ready.

In interventions, you're witnessing that consent,

maybe using an interpreter if there is a language barrier, and then administering the study agent with absolute accuracy.

It's a lot of responsibility.

Yeah.

You are the guardian of the research protocol and the guardian of the patient at the exact same time.

It is.

The two roles have to coexist.

I want to shift gears now to the history of legislation.

We've mentioned days like 1993 and 1992, but I want to go way, way back because the drug laws we have today didn't just appear out of thin air.

They were usually written in ink after a tragedy was written in blood.

That is a very grim but very accurate way to put it.

Drug legislation in the US is almost entirely reactive.

Something terrible happens and then a law gets passed to prevent it from happening again.

So let's start in the Wild West days, the turn of the 20th century.

1906, the Pure Food and Drug Act.

Before this, you could sell anything.

You could put colored water and alcohol in a bottle, call it Dr.

Wonderful's Great Panacea, and sell it.

Or worse, you could put opium or cocaine in it and sell it to soothe crying babies.

The famous snake oil era.

Exactly.

The 1906 act prohibited the sale of misbranded and adulterated drugs.

Basically, the label on the bottle had to match what was actually inside the bottle.

You couldn't say it was pure if it was full of sawdust.

Did it say the drug had to work?

Nope.

Did it say it had to be safe?

No, it just had to be what you said it was.

You could sell pure arsenic for babies colic as long as it was, in fact, pure arsenic.

That is absolutely terrifying.

It was.

Then in 1912, the Shirley Amendment tried to prohibit false therapeutic claims, but it had a fatal flaw.

The government had to prove intent to defraud.

Which is almost impossible to do legally.

You can just say, oh, I didn't intend to trick them.

I truly, truly believe this sawdust cures cancer.

Exactly.

So the law was completely toothless.

Then we jump to 1938.

This is the first major, major turning point.

The Federal Food, Drug, and Cosmetic Act.

And what triggered this one?

Another tragedy.

A terrible one.

It's known as the elixir sulfenolamide disaster.

A company created a liquid form of a sulfa drug, which was a new antibiotic at the time, to dissolve the powder they used diethylene glycol.

Aethylene glycol.

It's like antifreeze.

Essentially, yes.

It's a key component of antifreeze, and it is highly toxic to human kidneys.

They didn't test it for safety because the 1906 law didn't require them to.

Oh, no.

They shipped it out.

Over 100 people died, many of them children, in absolute agony from kidney failure.

That is horrific.

It shook the entire nation.

Congress reacted by passing the 1938 act, which for the first time, empowered the FDA to ensure a drug was safe before it could be marketed.

It shifted the burden of proof from the government to the manufacturer.

So 1938 gives us safety.

But notice, we still haven't talked about effectiveness.

Not yet.

That took another, even more famous tragedy.

1962.

The Kefalver -Harris Amendment.

And this was the thalidomide tragedy.

Thalidomide.

That name still sends shivers down the spine of the entire medical community?

It does.

It was a sedative, and it was widely used in Europe, Canada, and other places for morning sickness and pregnant women.

It caused foc -a -melia -severe catastrophic limb deformities in thousands and thousands of babies.

I've seen the photos.

It's just heartbreaking.

The 1962 amendment drastically tightened safety controls, especially for experimental drugs.

But it added a brand new requirement.

Proof of efficacy.

You now had to scientifically prove the drug actually worked for what you claimed it worked for.

It also required adverse reaction labeling on the package insert.

So to recap, 1938 gave us safety.

1962 gave us effectiveness.

Correct.

Those are the two pillars.

Then in 1970, we got the Comprehensive Drug Abuse Prevention and Control Act.

This is the law that gave us the schedule system for controlled substances.

This is a huge part of daily nursing practice.

We hear schedule two, and we immediately know that means strict rules.

Let's break down the logic here.

It's based on misuse potential and medical use.

Right.

Schedule one is the most restrictive category.

These are substances with a high abuse potential and no accepted medical use in the United States.

Examples.

Heroin, LSD,

and under federal law, cannabis.

And I think an observant listener might pause at cannabis and no accepted medical use given all the current state laws.

And they should.

It is a major point of tension and conflict between federal law and state law right now.

But federally, as of this recording, it remains schedule one.

Okay.

Then schedule two.

High misuse potential, a severe liability for dependents, but they do have an accepted medical use.

This is where you find your heavy hitters.

Methadone, oxycodone, fentanyl, Ritalin.

So it's wild that fentanyl is technically less restricted than marijuana in this specific classification system just because it has a recognized medical use.

Strictly speaking, based on the definition of accepted medical use, yes.

But the practical controls on schedule two drugs are incredibly tight.

Schedule three.

A lower misuse potential than IR2.

Abuse might lead to moderate physical dependence or high psychological dependence.

Think of things like acetaminophen with codeine, ketamine, or anabolic steroids.

Schedule four.

Low misuse potential.

This is where you find many of the benzodiazepines like alprazolam, which is Xanax, and diazepam, which is Valium.

Tramadol is also in this category.

And finally, schedule five.

The lowest potential for abuse.

Think of cough preparations with very small amounts of codeine.

Now for the nurse, these schedules aren't just trivia you memorize for a test.

They dictate your entire workflow.

Absolutely.

You have to account for every single pill, every single milliliter.

You maintain a perpetual log, and wastage is a huge, huge deal.

Wastage.

That sounds like just throwing something away.

It is, but it's a highly controlled process.

Let's say the doctor's order is for two milligrams of morphine.

The vial it comes in contains four milligrams.

You have to waste the other two milligrams.

And you cannot do this alone.

Never.

Another licensed nurse must physically watch you dispose of that medication, and then you both sign the log.

This is to prevent diversion, to make sure you aren't slipping that extra two milligram into your pocket.

If the count is off at the end of the shift, nobody goes home until it's resolved.

It's that serious.

It is that serious.

Let's move through some of the more modern legislation quickly, because the laws just kept evolving.

1983, the Orphan Drug Act, we mentioned that with the rare diseases.

Right.

It gave tax credits and other incentives to companies to develop drugs for those small orphan populations.

Then 1994, the Dietary Supplement Health and Education Act.

This one almost feels like a step backward in regulation.

In a way, it was.

It created a new category and classified dietary supplements as food, not drugs.

This means the FDA regulates them very differently.

They don't have to prove they work.

They don't have to prove efficacy before hitting the market.

The FDA can pull them if they're proven to be unsafe, but the burden of proof is different.

It created the massive supplement industry we see today, but it puts the burden on the consumer to be very careful about what they're buying.

Then we had the Pediatric Acts in 2002 and 2003.

The Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.

The insight here was simple, but revolutionary at the time.

Children are not small adults.

Right.

Their metabolism is different.

Their organs are still developing.

You can't just take an adult pill and cut it into quarters and assume it's safe and effective.

These acts incentivize and, in some cases, required that drugs be specifically tested in pediatric populations.

And finally, let's touch on the Nurse Practice Acts.

These aren't federal laws, right?

No.

These are state laws.

Every single state has its own.

They define what you, as a nurse, can legally do in that state.

And generally, nurses cannot prescribe or administer drugs without a legitimate provider's order.

Violating your state's Nurse Practice Act is the fastest way to lose your license.

You have to know the rules of the state you are physically standing in.

You do.

Before we leave regulation, let's look globally for a second.

Counterfeit drugs.

It's a terrifying shadow industry.

The WHO estimates that roughly 10 % of global drugs are counterfeit.

In some developing areas, that number is much, much higher.

The most common fakes are things like antibiotics, erectile dysfunction drugs, and, horrifically,

cancer drugs.

A fake cancer drug.

I can't even imagine.

Yes, you're evil.

The nurse has a role here in consumer education.

Tell patients to look for the VIPPS seal, that's the Verified Internet Pharmacy Practice Site seal, if they're buying medications online.

And just as importantly, listen to your patient.

If they say, this pill tastes different, or the packaging looks a little lighter than last time, don't just dismiss it, report it.

Okay, let's move to section nine.

Drug names.

This is a classic stumbling block for students.

The whole chemical generic brand name thing.

Okay, let's break it down.

The chemical name is the long, complicated science name based on the molecular structure like N4 -hydroxyphenylacetamide.

You will never, ever use that at the bedside.

You're not gonna walk in and say, here is your N4 -hydroxy.

No, you are not.

You will use the generic name.

This is the official non -proprietary name given by the U .S.

Adopted Names Council.

Acetaminophen, ibuprofen.

It's universally accepted, and it's always written in lowercase.

And the brand name.

That's the marking name.

It's trademarked by a specific company.

Tylenol, Advil, Motrin.

It's always capitalized.

Now for the big question that every patient asks, is the generic just as good as the brand name?

This is the concept of bioequivalence.

By law, the generic drug must have the same active ingredient, the same strength, and the same dosage form as the brand name drug.

So the engine is exactly the same?

The engine is the same, yes.

But the paint job and the chassis might be different.

The inert ingredients, the binders, the fillers, the dyes that give it its shape and color can vary.

And does that actually matter?

For most drugs, for most people, no.

If the generic is therapeutically equivalent, meaning it has less than a 20 % variance in absorption and distribution, it gets an A rating in the FDA's Orange Book.

It's considered interchangeable.

But there is a very specific safety alert in the text about this.

Yes.

For a small number of drugs with a narrow therapeutic index, that small variance can matter a lot.

What kinds of drugs are we talking about here?

Blood thinners like warfarin,

antiepileptics like phenytoin.

For these drugs, the window between an effective dose and a toxic dose is very small.

If the absorption changes even a tiny bit, you could either have a seizure because you got too little drug, or you could have toxicity because you got too much.

So what's the advice for patients on those drugs?

For these specific patients, we caution them not to switch between different generic manufacturers constantly.

If their pharmacy switches from, say, Tiva phenytoin to Sandus phenytoin, they need to be aware and monitor for any changes.

The best advice is to try and stick to one if possible.

That is a crucial clinical pearl.

It really is.

Okay, finally, let's talk about the drug aisle at the grocery store.

Over -the -counter drugs,

OTCs.

It's a massive $41 billion market.

And there is a very dangerous perception out there that OTC means completely safe.

If I can buy it at a gas station next to the chewing gum, it can't possibly hurt me.

Which is dead wrong.

OTCs are safe if they are used correctly for the right person for a short period of time.

But the risks are very real.

Let's look at the label first, the drug facts label.

It was standardized by the FDA in 2002 to make it easier to read.

It always has the same format.

Active ingredients, purpose, uses, warnings, and then directions.

It's all there, but people have to actually take the time to read it.

Let's dive into some of the specific risks mentioned in the text.

Ibuprofen, Advil, Motrin.

Ibuprofen is an NSAI.

It's great for pain and inflammation, but it works by inhibiting prostaglandins, some of which protect the lining of the stomach and the kidneys.

So it can be hard on the kidneys?

It can be nephrotoxic, toxic to the kidneys, especially with long -term use or in people with existing kidney problems.

It also causes fluid and sodium retention.

So if you have a patient with heart failure or high blood pressure.

Ibuprofen can make both of them worse.

It can directly counteract their blood pressure medications.

It even carries a boxed warning from the FDA for increased risk of heart attack and stroke.

And acetaminophen, Tylenol.

This is the scary one because it's in everything.

The big risk with acetaminophen is hepatotoxicity, liver damage,

severe, irreversible liver damage.

What's the mechanism there?

When your body metabolizes acetaminophen, it creates some toxic byproducts.

Normally, your liver has a substance called glutathione that breaks these down safely.

But if you take too much, you completely overwhelm the liver's ability to cope and those toxic metabolites just start destroying liver cells.

And too much isn't actually that much, is it?

For a healthy adult, the maximum daily dose is four grams or 4 ,000 milligrams.

But here is the trap.

You have a bad cold, you take a couple Tylenol for your headache.

Then before bed, you take a dose of a cold medicine like NyQuil or Daquil, which also contains acetaminophen.

You're doubling up without even realizing it.

You're doubling up.

That's the combination product risk.

That's why the FDA limited the amount of acetaminophen allowed in prescription combination drugs like Vicodin to 325 milligrams per tablet to create a safety buffer.

And what about aspirin?

Aspirin can be a trigger for asthma attacks in some sensitive patients.

But the critical warning, the one every parent needs to know, is it's linked to Ray syndrome in children.

Ray syndrome.

It's a rare but incredibly serious life -threatening condition that causes swelling in the liver and the brain.

It almost always happens when children or teenagers who are recovering from a viral infection like the flu or chickenpox take aspirin.

So the absolute rule of thumb is no aspirin for kids with fevers.

Generally, yes.

Stick to acetaminophen or ibuprofen if they are the appropriate age, but avoid aspirin in any viral context for children and teens.

The text suggests a mnemonic for patients to remember.

Safer.

Yeah, it's a good one.

Speak up, ask questions, find the facts, evaluate your choices, and read the labels.

It's a simple checklist to empower patients to keep from hurting themselves with these supposedly safe drugs.

Let's wrap this up with a quick look at resources.

If I'm a nursing student and I need to know if a drug is safe, where do I look?

Not Wikipedia, right?

Please no.

Use authoritative, evidence -based sources.

The American Hospital Formulary Service or AHFS is considered the gold standard for unbiased drug information.

The USPDI is also excellent.

And for patients.

If a patient asks you where they can look something up.

Medline Plus.

It's run by the National Library of Medicine.

It's accurate, it's reliable, and it's written in plain language that people can actually understand.

Tell them to avoid random health forums and blogs.

So we have traveled a really long road today.

From the 12 -year development cycle and the billion -dollar investments to the ethical pillars of the Belmont Report.

We've seen how history, from snake oil to thalidomide, shaped the laws that protect all of us today.

We've walked a mock drug or cardio comm through the rigorous phases of clinical trials.

And we've looked at the very practical, everyday dangers of drug names and OTCs.

It really reinforces that pharmacology isn't just about memorizing flashcards of side effects.

No, not at all.

It's about understanding the entire system.

And for the nurse, you are the final checkpoint in that massive, complex system.

You are the one standing there at the bedside, ensuring that respect for persons isn't just a theory in a textbook, but a living practice.

You're the one checking the name, checking the dose, and watching for the reaction.

You are the safety net.

You are the final safety net.

I wanna leave you, our listener, with a final thought to mull over.

We talked about the constant push for speed -expedited approvals, breakthrough therapy designations.

We all want cures faster, obviously.

But in a system that is based on a very delicate risk -benefit ratio,

are we shifting the balance?

By speeding things up, are we, as a society,

accepting a slightly higher risk in exchange for that hope of a faster cure?

It's the eternal question of modern medicine, isn't it?

How fast is too fast?

Something to ponder.

Thank you for joining us on this deep dive into drug development and ethics.

It's been a real pleasure.

This has been the Last Minute Lecture Team signing off.

Stay curious and stay safe.